Cargando...

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox

The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL patients continue to relapse, and sooner or later, most require subsequent lines of treatment...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Autores principales: Robak, Tadeusz, Janus, Agnieszka, Jamroziak, Krzysztof, Tiacci, Enrico, Kreitman, Robert J.
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2021
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8269075/
https://ncbi.nlm.nih.gov/pubmed/34202156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10132800
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!